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Abstract
Background: The objective of this study was to evaluate the efficacy and safety of pemetrexed plus cisplatin/
carboplatin in locally advanced or metastatic non-small cell lung cancer (NSCLC) patients previously treated with 
platinum-based chemotherapy.
Methods: Fifty-three locally advanced or metastatic non-small cell lung cancer patients previously treated with 
platinum-based chemotherapy received pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin area under 
the curve (AUC) 5 every 21 days, with dexamethasone, folic acid and vitamin B12 being administered.
Results: Median age was 52 years. Eastern Cooperative Oncology Group (ECOG) performance status was 0-2. Thirty-
eight patients had stage IV tumors. Thirty-seven patients had adenocarcinoma (including 6 alveolar carcinoma 
patients), and fourteen patients had squamous cell carcinoma. Thirty-four patients were treated in second line, 15 in 
third line, and 4 in fourth line. Seven patients (13.2%) showed partial response; Thirty-six (67.9%) had stable disease. The 
median progression free survival time was 6.0 months and the median overall survival time was 10.0 months. The 1-
year survival rate was 40.9%. Five (9.4%) and four (7.5%) patients experienced grade 3 or 4 leukopenia and 
thrombocytopenia, respectively. Nonhematological toxicities included grade 3 nausea/vomiting in 1 patient (1.9%), 
grade 3 rash in 1 patient, grade 4 diarrhea in 1 patient (1.9%) and grade 4 creatinine increase in 1 patient (1.9%).
Conclusion: Locally advanced or metastatic NSCLC patients previously treated with platinum-based chemotherapy 
could benefit from pemetrexed plus cisplatin/carboplatin chemotherapy with tolerable adverse events.
Background
Lung cancer is the most common cause of death from
cancer among men and women in the world [1]. Non-
small cell lung cancer (NSCLC) accounts for 80% of all
cases of lung cancer , with 65% to 75% of them ha ving
locally advanced or metastatic disease [2,3].
Combination chemotherapy is regarded as the standard
treatment of unresectable locally advanced or metastatic
NSCLC. Platinum-based chemotherapy with a third-gen-
eration agent (gemcitabine, paclitaxel, docetaxel, or
vinorelbine) has significantly improved median survival
and quality of life in those patients [4]. Despite these
advances, therapeutic results are still far from optimal.
Most patients receiving front line chemotherapy experi-
ence disease progression [5].
The current options for the second line treatment of
locally advanced or metastatic NSCLC are docetaxel,
pemetrexed and erlotinib. Docetaxel is the first drug
approved for second line treatment [5]. Pemetrexed was
approved in second line therapy in NSCLC on the basis of
a phase III trial comparing pemetrexed versus docetaxel.
In this trial, pemetrexed showed a similar clinical activity
and a lower rate of myelosuppression compared to doc-
etaxel [6-8]. Erlotinib, an epidermal growth factor recep-
tor inhibitor, was approved in the U.S. and Europe for
NSCLC second line treatment after a study showed its
superiority over best supportive care (BSC) in recurrent
NSCLC patients [9].
Pemetrexed is a multitargeted antifolate cytotoxic che-
motherapy agent, which inhibits at least three target
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enzymes in the folate pathway (thymidylate synthase,
dihydrofolate reductase, and glycinamide ribonucleotide
formyl transferase). As a consequence, pemetrexed inter-
feres with the synthesis of both pyrimidine and purine,
thereby effectively inhibiting both DNA and RNA synthe-
sis[10] Several reports have documented the efficacy of a
platinum based combination therapy with pemetrexed is
similar to other standard platinum doublets [11-13].
Pemetrexed in combination with cisplatin was recently
granted as first-line treatment of advanced non-
squamous histology NSCLC patients [14-17].
In December 2005, pemetrexed was approved in China.
Platinum-based chemotherapy played an important role
in the treatment of NSCLC [18,19]. Clinical trials have
proved the safety of pemetrexed in combination with
platinum [20-22]. We designed the study to gain clinical
experience with pemetrexed plus platinum in previously
treated patients with locally advanced or metastatic
NSCLC. The objective of this study was to evaluate the
efficacy as well as safety of pemetrexed plus platinum in




All consecutive patients with histologically confirmed
previously treated locally advanced or metastatic NSCLC
were enrolled in this study. All patients had experienced
platinum-based chemotherapy, and none of them had
received pemetrexed as part of the treatment. For all
patients, prior chemotherapy had been completed at least
21 days prior to the start of the study and the patients
have recovered from any acute toxic effect of previous
therapy. Further inclusion criteria were: age < 70 years
and life expectancy > 8 weeks, Eastern Cooperative
Oncology Group (ECOG) performance status was 0-2,
and adequate haematologic (absolute neutrophil ≥ 1.5 ×
109/L, platelets ≥ 100 × 109/l, and hemoglobin ≥ 9 g/dL),
hepatic (total bilirubin < 1 fold of the upper limit of nor-
mal value, aspartate aminotransaminase and alanine ami-
notransferase <1.5 fold of the upper limit of normal value,
and it may be elevated to 3 fold of the upper limit of nor-
mal value in patients with known hepatic metastases),
and renal (a calculated creatinine clearance rate of <45
ml/min) functions.
Patients with signs of malnourishment or > 10% weight
loss in the past 6 weeks, or others serious concomitant
disorders were excluded from the therapy. Patients were
discontinued from the therapy in the case of evidence of
progressive disease or unacceptable toxicity despite dose
adjustment.
This study was conducted according to ICH Good
Clinical Practice guidelines, including obtaining written
informed consent from all patients.
Study Medication
Pemetrexed 500 mg/m2 was intravenously administered
over 10-min on day 1 of a 21-day cycle, followed by cispl-
atin 75 mg/m2 administration intravenously over a 2-h
infusion or carboplatin AUC 5 a 30-min infusion after
pemetrexed administration. If a patient had been treated
with cisplatin in last line chemotherapy, we gave the
patient pemetrexed/carboplatin combination chemother-
apy. Otherwise, we gave the patient pemetrexed/cisplatin
combination chemotherapy. Dexamethasone 4 mg was
taken orally twice daily on the day before, the day of, and
the day after each dose of pemetrexed. Folic acid supple-
mentation 400 μg was taken orally daily beginning 1 week
prior to the first dose of pemetrexed and continued until
3 weeks after study therapy discontinuation. Vitamin B12
1000 μg was intramuscularly injected, starting 1 week
prior to day 1 of cycle 1 and repeated every 9 weeks until
study discontinuation.
If a patient experienced unacceptable toxicities, treat-
ment was delayed for up to 42 days from day 1 of any
cycle to allow recovering from toxicities. When Common
Toxicity Criteria (CTC) grade 3/4 symptoms resolved,
therapy was resumed at 75% of the previous dose. Any
patient requiring >42 days recovery time or > 2 reduc-
tions due to toxicity was to be withdrawn from the study.
If patient required radiotherapy during the study, peme-
trexed was discontinued until 2 weeks after the comple-
tion of radiotherapy.
Assessments
Baseline tumor measurements were taken no more than 2
weeks before treatment. At the end of the treatment
period, the best tumor response rate was evaluated using
the same imaging technique that was used at baseline and
the Response Evaluation Criteria in Solid Tumors
(RECIST) were recommended [23]. The progression free
survival (PFS) was defined as the time from study entry to
disease progression or death. The overall survival time
(OS) was the time from study entry to death due to any
cause. The safety measures including adverse events,
physical examinations and clinical laboratory tests
(hematology, blood chemistry, hepatic functions and
renal functions) were completed before each cycle. Toxic-
ities were graded using version 2.0 of the National Cancer
Institute Common Toxicity Criteria [24].
Statistical Methods
W e  p l a n n e d  t o  h a v e  u p  t o  5 3  q u a l i f i e d  p a t i e n t s  t o  b e
enrolled in a two stage sequential, non-comparative study
with the possibility of stopping the study early for lack of
efficacy. Nineteen qualified patients were enrolled in the
first stage. If at least twelve patients achieved disease con-
trol, thirty-four additional patients were accrued. The sig-
nificance level (i.e., the probability of rejecting the HoZhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:38
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when it is true) is 5%. The power (i.e., the probability of
rejecting Ho when the alternative hypothesis is true) is
80% [25-29].
The statistical analysis was performed using the Statis-
tical Package for Social Science (SPSS) 17.0. Summary
statistics were given for patient characteristics, treatment
administration and all safety variables. Frequencies are
reported as number and percentage. Efficacy analyses
and safety analyses were conducted on all patients who
received at least one dose of study drug. The objective
response of chemotherapy was defined with an overall
best response during treatment. PFS and OS time were
analyzed by means of Kaplan-Meier method.
Results
Between December 2005 and May 2008, a total of 53
patients entered the study. The baseline patient charac-
teristics were listed in Table 1. The median age was 52
years (range, 34-68 years), and there were 39 male and 14
female patients. Most patients had a good performance
status, but thirteen patients had ECOG performance sta-
tus 2. Thirty-eight patients had stage IV tumors. Thirty-
seven patients had adenocarcinoma (including 6 alveolar
carcinoma patients). Fourteen patients had squamous-
cell carcinoma. One patient had large cell carcinoma.
One patient had mixed carcinoma. The median interval
from the primary diagnosis to the beginning of the study
treatment was 8.8 months. The follow-up period varied
from 1 to 42 months (mean 11.3 months, median 10
months). Thirty-two patients received pemetrexed plus
cisplatin chemotherapy, and twenty-one patients received
pemetrexed combined with carboplatin therapy. Out of
these 53 patients, 34 were treated in second line (64.2%),
15 in third line (28.3%), and 4 in fourth line (7.5%). Every
patient received at least one cycle of chemotherapy of
pemtrexed with cisplatin/carboplatin. The total number
of chemotheraphy cycles given was 189, while the median
number of cycles received was 3.0 (range 1-10). 12
patients (22.6%) had dose modification at least in one
cycle: The pemetrexed dose was reduced due to adverse
events in 4 patients and was delayed (mostly due to
adverse events) in 10 patients. At the end of the follow-up
in May 2009, 2 patients were lost to follow-up after tumor
recurrence, 6 patients had no disease progression, and 17
patients were still alive.
Efficacy
Of the 53 patients treated with pemetrexed plus plati-
num, no complete response (CR) were observed, whereas
7 patients achieved partial response (PR). The objective
response rate (ORR = CR+PR) was 13.2%. In the remain-
ing patients, 36 (67.9%) achieved stable disease (SD), 10
(18.9%) had progressive disease (PD). Thus, the disease
control rate (DCR = CR+ PR+ SD) in this study was
81.1%. Tumor response is summarized in Table 2. The
median PFS time was 6.0 months [95% confidence inter-
val (CI): 4.6 to 7.4] and the median OS time was 10.0
months (95% CI: 9.1 to 13.0). Kaplan-Meier plots for PFS
and OS are displayed in Figure 1 and 2, respectively. The
1-year survival rate was 40.9%.
Toxicity
Toxicity was evaluated in all patients and in all cycles, and
it was showed in Table 3. Forty-two patients (79.2% of
those treated) reported at least one adverse event during
the study, 7 patients (13.2%) and 5 patients (9.4%) experi-
enced grade 3 and grade 4 adverse events, respectively.
The most common adverse events were leucopenia
(49.1% of treated patients), nausea/vomiting (49.1% of
treated patients), Neutropenia (37.7% of treated patients),
Thrombocytopenia (32.1% of treated patients) and
fatigue (18.9% of treated patients). Gastrointestinal disor-
ders (49.1%) and blood system disorders (49.1%) were the
system organ classes with the highest incidence of
adverse events related to treatment.
Table 1: Demographic data for patients treated with 
pemetrexed plus platinum (n = 53).
Patient criteria N (%)
Patient number 53




Weight, kg: mean ± SD 
(range)










Alveolar carcinoma 6 (11.3)
Squamous carcinoma 14 (26.4)
Large cell carcinoma 1(1.9)
Mixed carcinoma 1(1.9)
No. chemotheraphy line
Second line 34 (64.2)
Third line 15 (28.3)
Fourth lines 4 (7.5)Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:38
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The incidences of CTC grade 3/4 adverse events were
blood system disorders (16.9%), gastrointestinal disorders
(3.8%), kidney function disorders (1.9%) and rash (1.9%).
Grade 3 adverse events reported included leukopenia (3
patients), thrombocytopenia (2 patients), nausea/vomit-
ing (1 patient), and rash (1 patient). Grade 4 adverse
events included leukopenia (2 patients), thrombocytope-
nia (2 patients), diarrhea (1 patient) and Creatinine
increase (1 patient).
In the study endpoint, 34 patients (63.9%) died due to
disease progression: 1 patient (1.9%) died within 30 days
of treatment discontinuation, and 33 patients died after
30 days from treatment discontinuation.
Discussion
A multicenter, international, randomized phase III trial
reported by Hanna et al compared single-agent peme-
trexed with docetaxel in previously treated NSCLC
patients. Until that trial, docetaxel was the only approved
cytotoxic chemotherapy for second-line NSCLC treat-
ment. Five hundred and seventy-one patients were ran-
domized to pemetrexed 500 mg/m2 or docetaxel 75 mg/
m2 on day 1 of a 3-week cycle. Dexamethasone, folic acid
and vitamin B12 were given every cycle. Overall response
rates for pemetrexed and docetaxel were 9.1% and 8.8%,
respectively (P = 0.105). The stable disease rate was 45.8%
for pemetrexed and 46.8% for docetaxel. Both treatment
groups exhibited similar median progression-free sur-
vival and 1-year survival rates of 2.9 months and 29.7%,
respectively. Median survival for pemetrexed and doc-
etaxel was 8.3 and 7.9 months, respectively (P = 0.226).
There was no difference in symptom improvement
between the pemetrexed and docetaxel groups (P =
0.145). Hematologic adverse effects--grade 3/4 neutrope-
nia (40.2% versus 5.3%; P < 0.001), febrile neutropenia
(12.7% versus 1.9%; P < 0.001), and neutropenic infec-
tions (3.3% versus 0%; P = 0.004)--were significantly
greater in the patients who received docetaxel versus
those who received pemetrexed. 125 elevation of ALT
was the only adverse event occurring more often in the
pemetrexed group (P = 0.028). The results of the phase III
study indicated pemetrexed is a viable option for second-
line treatment in NSCLC, and provided an objective
response and symptomatic benefit in conjunction with a
favorable safety profile. Based on this trial, the U.S. FDA
approved pemetrexed for second-line treatment of locally
advanced or metastatic NSCLC [6].
In our study, 53 patients were enrolled. All patients had
experienced platinum-based chemotherapy. Most of
patients (>70%) had good clinical conditions (ECOG PS 0
or 1). The patients treated with pemetrexed plus plati-
num were supplemented with dexamethasone, folic acid
and vitamin B12. The addition of folic acid and vitamin
B12 supplementation markedly reduced the toxicity pro-
file of pemetrexed, as shown in a previous trial comparing
pemetrexed administered with or without vitamins [30].
The median number of cycles received was 3. No patient
achieved CR. Seven of the 53 patients (13.2%) showed PR.
The ORR (13.2%) is higher than that of single pemetrexed
(8.8%) reported by Hanna et al. The stable disease rate
was 67.9% in this study, which was markedly higher than
that of single pemetrexed (45.8%) in Hanna's study. The
Figure 1 Kaplan--Meier curve of progression-free survival for pa-
tients treated with pemetrexed plus platinum (n = 53).
Figure 2 Kaplan--Meier curve of overall survival for patients 
treated with pemetrexed plus platinum (n = 53).Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:38
http://www.jeccr.com/content/29/1/38
Page 5 of 7
DCR for pemetrexed plus cisplatin/carboplatin in this
study and single pemetrexed in Hanna's study were 81.1%
and 54.6%, respectively, which also have a significant dif-
ference. The median progression-free survival was 6.0
months, which was two times longer than that of single
pemetrexed (2.9 months) in Hanna's study. The median
OS time was 10.0 months, which was also longer than
that of single pemetrexed (8.3 months). The 1-year sur-
vival rate was 40.9%, which was higher than that of single
pemetrexed (29.7%) in Hanna's study. Compared with
pemetrexed single agent chemotherapy, our study
showed that locally advanced or metastatic NSCLC
patients having experienced platinum-based chemother-
apy might acquire a higher objective response rate, higher
disease control rate, longer PFS, longer OS and higher 1-
year survival rate from pemetrexed combined with plati-
num chemotherapy. The main reason we achieved better
results should be due to the addition of platinum chemo-
therapy drugs. Of course, to exclude the impact of race
factor, we need further randomized controlled study.
In our study, the most frequent hematological toxicities
were neutropenia and thrombocytopenia (any grade) and
the most frequent nonhematological toxicities were nau-
sea/vomiting, fatigue, pyrexia and rash (any grade). The
incidence of grade 3/4 neutropenia and thrombocytope-
nia was 9.5% and 7.6%, which was higher than that of
pemetrexed single agent chemotherapy in Hanna's ran-
domized phase III study (5.3% and 1.9%). The incidence
of grade 3/4 Anemia was 0, which was 4.2% in that ran-
domized phase III study. The nonhematological toxicities
were similar to single pemetrexed observed in Hanna 's
study. Although the incidence of neutropenia and throm-
bocytopenia in pemetrexed plus cisplatin/carboplatin
chemotherapy for previously treated locally advanced or
metastatic NSCLC patients was slightly higher than pem-
etrexed single chemotherapy, the adverse events were tol-
erable. After treated, all patients acquired recovery from
hematological toxicities. In this study, no patient died of
chemotherapy.
Another study comparing pemetrexed with pemetrexed
plus carboplatin in patients experiencing relapse after
platinum-based chemotherapy showed that adding car -
boplatin to second-line pemetrexed treatment signifi-
cantly increases ORR and PFS in patients with NSCLC
after having received first-line platinum-based chemo-
therapy [31]. This conclusion is consistent with our
results. However, the patients in the latter study did not
receive a longer OS for pemetrexed combined with car-
boplatin chemotherapy compared with pemetrexed sin-
gle agent chemotherapy, which may be associated with
the application of different platinum. In our study, 21
patients (40% of all patients enrolled) received peme-
trexed/carboplatin chemotherapy, while the remaining 32
Table 2: Response for patients treated with pemetrexed 
plus platinum (n = 53).
Response N (%) 95% CI (%)
CR - -
PR 7(13.2) 5.48 to 25.34
SD 36(67.9) 56.68 to 80.08
PD 10(18.9) 9.44 to 31.97
CI, confidence interval; -, no data.
Table 3: Toxicity for patients treated with pemetrexed plus platinum (n = 53).
Adverse event Any grade ≥ 1 Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 26 (49.1) 10 (18.9) 11 (20.8) 3 (5.7) 2 (3.8)
Neutropenia 20 (37.7) 6 (11.3) 9 (17.0) 3 (5.7) 2(3.8)
Thrombocytopeni
a
17 (32.1) 11 (20.8) 2 (3.8) 2 (3.8) 2 (3.8)
Anemia 8 (15.1) 4 (7.5) 4 (7.5) - -
ALT/AST 3 (5.7) 3 (5.7) - - -
Nausea/Vomiting 26 (49.1) 16 (30.2) 9 (17.0) 1 (1.9) -
Diarrhea 1 (1.9) - - - 1 (1.9)
Creatinine 1 (1.9) - - - 1 (1.9)
Pyrexia 5 (9.4) 4 (7.5) 1 (1.9) - -
Fatigue 10 (18.9) 10 (18.9) - - -
Rash 5 (9.4) 1 (1.9) 3 (5.7) 1 (1.9) -
Inflammation 3 (5.7) - 3 (5.7) - -
Data are number of patients with rates in bracketsZhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:38
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patients (60% of all patients enrolled) received peme-
trexed/cisplatin chemotherapy. All of the patients
received pemetrexed/carboplatin chemotherapy in the
latter study. In addition, racial differences may also be a
factor. Our data came from the Chinese people, and their
data came from non-Asians.
In short, the study showed, locally advanced or meta-
static NSCLC patients previously treated with platinum-
based chemotherapy could benefit from pemetrexed plus
cisplatin/carboplatin chemotherapy with tolerable
adverse events.
For patients with advanced or metastatic cancer, the
quality of life is important. In our study, we found some
patients' quality of life was obviously increased even
though their tumor was stable or progressive after che-
motherapy. Due to a minor flaw in the original study
design, there are no available data on whether patients'
qualities of life were increased or not.
Pemetrexed produces its cytotoxic effect by blocking
intracellular thymidylate synthase, dihydrofolate
reductase, and glycinamide ribonucleotide formyl trans-
ferase. A deeper knowledge of those target enzymes may
be used in the future to identify patients' responses to
pemetrexed [32]. The targeted compounds combined
with chemotherapy regimens might represent the next
step treatment of NSCLC and the characteristics of pem-
etrexed make it a candidate in therapies context.
This study reported clinical experience with peme-
trexed plus platinum for previously treated patients with
locally advanced or metastatic non-small cell lung cancer
and further prospective randomized clinical trials will
confirm whether pemetrexed combined with platinum is
a valid option for pretreated locally advanced or meta-
static NSCLC patients.
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